American Financial Tribune: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Financial Tribune.

Press releases published on May 17, 2026

Beyond Everest: Manaslu Circuit Trek Emerges as Nepal’s Next Big Adventure
Global Investment Executive Andy Nematalla Opens Up to Investors and Media on Emerging Market Opportunities
New York’s Climate Disclosure Push Is Increasing Pressure on Financial Institutions and Multistate Corporates
US Companies Are Moving Beyond Annual ESG Reporting Toward Continuous Climate Data Management
California’s Climate Disclosure Laws Are Raising the Bar for Scope 3 Reporting
AVITA Medical to Host Investor Webinar Briefing
Life360 Board of Directors Authorizes Up to $225 Million Multi-Year Share Repurchase Program to Offset Stock-Based Compensation Dilution
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
Goat Funded Trader Celebrates Three Years of Empowering the Global Trading Community
MZTI Investors Have Opportunity to Join The Marzetti Company Fraud Investigation with the Schall Law Firm
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges POET Technologies Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Power Solutions International, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Concorde International Group, Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET

Share this page:

Sign up for:

American Financial Tribune

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.